← FDA DRUG APPROVALS

FDA ANDA · ANDA076999

CLOPIDOGREL

Sponsor: TEVA

APPLICATION
ANDA076999
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-17
LATEST ACTION
2024-07-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CLOPIDOGREL BISULFATEPrescription
CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET · ORAL

Approval history

2024-07-22Labeling · Supplement 17 · standardAP
2024-07-22Labeling · Supplement 16 · standardAP
2020-03-24Labeling · Supplement 14 · standardAP
2020-03-24Labeling · Supplement 12 · standardAP
2020-03-24Labeling · Supplement 10 · standardAP
2020-03-24Labeling · Supplement 13 · standardAP
2020-03-24Labeling · Supplement 11 · standardAP
2015-10-28Labeling · Supplement 7 · standardAP
2015-03-09Labeling · Supplement 6 · standardAP
2015-03-09Labeling · Supplement 2 · standardAP
2015-03-09Labeling · Supplement 3 · standardAP
2012-05-17OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →